Abstract: The present invention belongs to the field of medicine, and provides a quinoline compound or a pharmaceutically acceptable salt thereof for treating Ewing's sarcoma, and particularly relates to use of compound I or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating Ewing's sarcoma and use of compound I or a pharmaceutically acceptable salt thereof in combination with a second therapeutic agent in the preparation of a combination medicament for treating Ewing's sarcoma. The chemical name of compound I is 1[[[4-(4-fluoro-2-methyl-1H-indo1-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropanamine.

Abstract: The present disclosure relates to a new use of anlotinib, and relates in particular to anlotinib inhibiting osteosarcoma and chondrosarcoma growth and metastasis. It has been discovered for the first time that anlotinib can inhibit osteosarcoma and chondrosarcoma growth and metastasis. Anlotinib can significantly inhibit the growth of the osteosarcoma cell lines 143B, U2OS, MG63 and SJSA, induce cycle arrest in said cell lines, and can also inhibit osteosarcoma cell line migration and invasion. It has also been discovered for the first time that anlotinib can enhance the killing effect of the chemotherapeutic drug cisplatin on osteosarcoma cells.